Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Parexel has signed an agreement with ASAN Medical Center (AMC) to accelerate Korea based drug development and commercialization programs.
Subscribe to our email newsletter
As per the agreement, clinical trial sponsors based regionally and internationally will have access to clinical trial services throughout Asia, with a focus on early phase development.
Parexel International COO Mark Goldberg said through the collaboration with ASAN they look forward to help clients take advantage of opportunities to support their Korea-based development and commercialization programs
"Parexel provides clients with patient access in key therapeutic areas for early phase development through our early phase units and global alliance network," Goldberg added.
ASAN president and CEO Seong-Wook Park said they are collaborating with Parexel through their Department of Clinical Pharmacology and Therapeutics to facilitate, and enhance the development and use of pharmacotherapeutics.